XML 30 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Operating Activities:    
Net loss $ (37,929) $ (20,472)
Reconciliation of net loss to net cash used in operating activities:    
Change in fair value of warrant liability (267) 401
Depreciation and amortization 1,636 1,216
Amortization of net premiums on investments 326   
Gain on disposal of property and equipment (37) (26)
Deferred rent 678 436
Non-cash stock-based compensation 1,784 1,668
Changes in operating assets and liabilities:    
Restricted cash 862 (838)
Accounts receivables (291) (504)
Unbilled receivables (1,624) 111
Prepaid expenses and other assets 639 (271)
Accounts payable and accrued expenses 623 (304)
Deferred revenue (199) 803
Lease incentives received 703 2,803
Net cash used in operating activities (33,096) (14,977)
Investing Activities:    
Capital expenditures (4,762) (2,202)
Proceeds from disposal of property and equipment 83 318
Net cash received from the Isconova AB acquisition 3,034   
Proceeds from maturities of investments 23,630 2,500
Purchases of investments (14,754) (15,763)
Net cash provided by (used in) investing activities 7,231 (15,147)
Financing Activities:    
Principal payments of capital leases (54) (90)
Principal payments of notes payable (305) (20)
Proceeds from notes payable 1,450 650
Restricted cash (1) (756)
Net proceeds from sales of common stock, net of offering costs of $6.1 million and $0.4 million, respectively 128,659 26,925
Proceeds from the exercise of stock options 1,194 49
Net cash provided by financing activities 130,943 26,758
Effect of exchange rate on cash and cash equivalents 16   
Net increase (decrease) in cash and cash equivalents 105,094 (3,366)
Cash and cash equivalents at beginning of period 17,399 14,104
Cash and cash equivalents at end of period 122,493 10,738
Supplemental disclosure of non-cash activities:    
Common stock issued in connection with the Isconova AB acquisition 41,942   
Property and equipment purchases included in accounts payable and accrued expenses 407 1,365
Deposit applied towards the purchase of laboratory equipment    500
Equipment acquired under a capital lease    399
Supplemental disclosure of cash flow information:    
Cash payments of interest $ 120